AstraZeneca PLC cash flow to debt ratio of 49.07% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

AstraZeneca PLC's free cash flow has increased 19.18% from $7.28B last year to $8.67B, signaling increasing performance

AstraZeneca PLC's debt to equity ratio is 0.64, which means that the company's assets are unhealthy financed, signaling financial risk.

AstraZeneca PLC's debt has decreased relative to shareholder equity from 0.74 last year to 0.64 today, signaling strengthened financials

AstraZeneca PLC has a net debt to EBITDA ratio of 1.21x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

AstraZeneca PLC's interest coverage ratio of 7.97 indicates that earnings with good margin can cover interest payments on company debt

AstraZeneca PLC's profit margin was 13.01% last year and is 17.02% this year, signaling increasing performance

AstraZeneca PLC's short-term liabilities of $30.62B exceed its short-term assets of $28.72B, signaling financial risk

AstraZeneca PLC's return on assets of 8.96% is higher than the 5.00% threshold, indicating efficient asset utilization

AstraZeneca PLC's return on equity of 21.68%, is higher than 15.00%, indicating good performance

AstraZeneca PLC's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

AstraZeneca PLC had positive net income in 5 out of 5 years, indicating stable and consistent earnings

AstraZeneca PLC has positive free cash flow, indicating the company generates cash after capital expenditures

AstraZeneca PLC has a free cash flow yield of 3.38%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

AstraZeneca PLC's yearly earnings has increased 45.77% since last year from $7.04B to $10.26B, signaling increasing performance

AstraZeneca PLC's yearly revenue has increased 8.63% since last year from $54.07B to $58.74B, signaling increasing performance

ROIC 12.69% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

AstraZeneca PLC's 3-year revenue CAGR of 9.82% is positive, indicating growing revenue over the past 3 years

AstraZeneca PLC had revenue growth in 5 out of 5 years, indicating consistent revenue performance

AstraZeneca PLC had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

AstraZeneca PLC is overvalued relative to its fair value price of 102.20 based on Base Cash Flow Valuation (DCF) model

AstraZeneca PLC has an earnings yield of 4.07%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

AstraZeneca PLC is overvalued relative to its fair value price of 73.53 based on Base EBITDA Valuation model

AstraZeneca PLC has an EV/EBITDA ratio of 14.15x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

AstraZeneca PLC is overvalued relative to its fair value price of 145.91 based on Base Earnings Fair Value model

AstraZeneca PLC has a PEG-ratio over 1 which is considered overvalued

AstraZeneca PLC has a price-to-book ratio of 5.07x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

AstraZeneca PLC has a price-to-sales ratio of 4.19x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue